Drugs / 2LHERP®
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT04235322 | Jan 2021 → Apr 2023 | genital herpes | Labo'Life | Terminated | No outcome recorded Stop: Enrollment |
| Phase 4 | NCT04065971 | Mar 2020 → Mar 2027 expected | herpes simplex infectious disease | Labo'Life | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 2LHERP | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04065971 ↗ |
| Route | Oral | “taking the content of one capsule a day, 15-30 minutes before breakfast, on an empty stomach” NCT04065971 ↗ |